Table 1.
Patient demographic and baseline characteristics
| Comparator (N = 2288)a | BIL (N = 3584)a | |
|---|---|---|
| Type 1 diabetes, n (%) | 610 (26.7) | 959 (26.8) |
| Age, years | 54.2 ± 13.3 | 54.0 ± 13.3 |
| Male, % | 58.0 | 54.7* |
| Race, n (%) | ||
| American Indian/Alaska native | 23 (1.0) | 37 (1.0) |
| Asian | 102 (4.5) | 182 (5.1) |
| Black/African American | 120 (5.2) | 182 (5.1) |
| Multiple | 21 (0.9) | 29 (0.8) |
| Native Hawaiian/Pacific Islander | 4 (0.2) | 7 (0.2) |
| White | 2018 (88.2) | 3143 (87.8) |
| Hispanic or Latino, n (%) | 332 (14.5) | 580 (16.2) |
| Region, n (%) | ||
| North America | 1019 (44.5) | 1611 (45.0) |
| European Union | 834 (36.5) | 1282 (35.8) |
| Japan | 42 (1.8) | 70 (2.0) |
| Other | 393 (17.2) | 621 (17.3) |
| BMI, kg/m2 | 30.7 ± 5.7 | 30.6 ± 5.7 |
| Body weight, kg | 88.6 ± 19.5 | 87.7 ± 19.1 |
| Duration of diabetes, years | 14.2 ± 9.4 | 13.8 ± 9.1 |
| HbA1c, % | 8.2 ± 1.1 | 8.2 ± 1.1 |
| Hypertension, n (%) | 1588 (69.4) | 2458 (68.6) |
| Triglycerides, mg/dL | 135 ± 86 | 139 ± 93 |
| Total cholesterol, mg/dL | 176 ± 38 | 177 ± 39 |
| LDL-C, mg/dL | 97 ± 33 | 98 ± 33 |
| HDL-C, mg/dL | 52 ± 16 | 52 ± 16 |
| History of myocardial infarction, n (%) | 93 (4.2) | 149 (4.4) |
| History of coronary revascularization, n (%) | 83 (3.8) | 121 (3.6) |
| History of coronary artery bypass graft, n (%) | 56 (2.6) | 92 (2.7) |
| Lipid lowering medication, n (%) | 1274 (55.7) | 1965 (54.8) |
| Statin | 1165 (50.9) | 1787 (49.9) |
| Non-statin | 316 (13.8) | 499 (13.9) |
| Smoking status, n (%) | ||
| Never used | 1279 (58.3) | 2013 (59.4) |
| Current used | 340 (15.5) | 507 (15.0) |
| Ever used | 575 (26.2) | 867 (25.6) |
Mean ± SD unless otherwise specified. p value >0.05 unless specified
* p = 0.031
aIncludes all randomized patients